Repare Therapeutics Inc Cash Flow-to-Debt Ratio
Repare Therapeutics Inc cash flow-to-debt ratio. Repare Therapeutics Inc (RPTX) has a Cash Flow-to-Debt Ratio of 0.23x as of September 2025, meaning its operating cash flow of $2.65 Million could theoretically repay 0% of its total liabilities ($11.62 Million) in one year. Check Repare Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Repare Therapeutics Inc (2018–2024)
Cash flow-to-debt ratio of Repare Therapeutics Inc from 2018 to 2024. Historical debt coverage capacity for Repare Therapeutics Inc across 7 annual periods. Check RPTX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Repare Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2024)
Repare Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2024. Year-by-year debt coverage analysis for Repare Therapeutics Inc. For the full cash flow conversion analysis, see Repare Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.01x | $-76.44 Million | $25.38 Million | ▲ +0.9% |
| 2023 | -3.04x | $-127.16 Million | $41.82 Million | ▼ -79948.9% |
| 2022 | 0.00x | $322.00K | $84.56 Million | ▲ +100.4% |
| 2021 | -1.07x | $-85.80 Million | $80.29 Million | ▼ -1133.9% |
| 2020 | -0.09x | $-6.08 Million | $70.26 Million | ▲ +94.0% |
| 2019 | -1.44x | $-18.43 Million | $12.83 Million | ▼ -313.4% |
| 2018 | -0.35x | $-12.62 Million | $36.31 Million | — |